LIP
10
1
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
10%
1 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
RHA® 3 Versus Restylane-L® for Lip Augmentation
3D Evaluation of the Lip Support in a Full-arch Implant-supported Rehabilitations
T1 Squamous Cell Carcinomas of the Lip
Assessment and Augmentation of Lip Appearance in Specific Study Populations
Four Hyaluronic Acid Fillers for Lip Augmentation
Facial Scanning for Lip Support Assessment in Full Arch Implant Rehabilitations